Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692334 | 0.84 | CTSS (0.37) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL9921704 | 0.83 | IDH1 (0.36) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL18602323 | 0.83 | IDH1 (0.36) | SOS2CTSKIDH1CTSSHSD11B1 | |
| Hydrochloric Acid SCHEMBL1111090 | 0.81 | TAAR1 (0.36) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL179277 | 0.80 | HSD11B1 (0.41) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL20738600 | 0.79 | SCN9A (0.38) | SCN9ASOS2CTSKCTSS | |
| SCHEMBL18793681 | 0.79 | SCN9A (0.38) | SCN9ASOS2CTSKCTSS | |
| SCHEMBL20738618 | 0.77 | IDH1 (0.38) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL20989227 | 0.77 | IDH1 (0.38) | SOS2CTSKIDH1CTSSHSD11B1 | |
| SCHEMBL22230336 | 0.77 | CTSK (0.39) | SOS2CTSKIDH1CTSSADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SCN9A 1935/4885SOS2 2440/4885CTSK 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.